Weight Loss Injections: Negative Effects Explained Honestly

What are the most common negative effects people actually notice?

Gastrointestinal symptoms lead the list by some distance. Nausea is the one most people mention first, sometimes as a mild background queasiness, occasionally enough to put you off a meal. Loose stools, constipation, indigestion, burping and stomach cramping all show up in trial data and in the experiences patients report. Fatigue and headache appear too, especially in the opening weeks.

The timing matters. These effects tend to cluster around two points: when treatment begins at the starter dose, and each time the dose increases. How side effects develop over a course of treatment follows a broadly predictable arc, noticeable early on, then settling as the body adjusts. That adjustment period can last anywhere from a few days to a fortnight.

Injection-site reactions (redness, mild swelling or itching at the spot where the pen was used) are also reported, though they're usually short-lived. Rotating sites between the abdomen, thigh and upper arm each week helps. Dizziness is less common but does occur, particularly if calorie intake drops sharply at the start. For a fuller breakdown of how these effects tend to unfold week by week, this overview of injection effects covers the pattern in more detail.

Are there negative effects serious enough to need medical help?

Yes, and being clear about this matters. Acute pancreatitis is the one the MHRA specifically highlighted in a Drug Safety Update published in January 2026: it is infrequent but can be serious. The signal to act is severe stomach pain that persists and radiates toward the back, with or without vomiting. That combination warrants a call to 111 or a visit to A&E, not a wait-and-see.

Gallbladder problems are another recognised risk. Rapid weight loss itself (independent of the medicine) can increase the likelihood of gallstones, so the combination deserves attention if you develop upper-right abdominal pain. Severe or repeated vomiting and diarrhoea can also lead to dehydration quickly enough to affect kidney function, staying well-hydrated and reducing the dose on medical advice if GI symptoms are severe is the practical response.

Allergic reactions are rare but possible. Signs include swelling of the face, lips or throat, or difficulty breathing after an injection. Anyone who notices these should seek emergency help immediately. Suspected side effects (including any that seem unexpected or severe) can be reported directly via the MHRA Yellow Card scheme, which exists to track safety signals in real-world use.

Do the negative effects outweigh the benefits for most people?

The short answer from the trial evidence is no, for the majority of participants. In the SURMOUNT-1 study of tirzepatide (Mounjaro) and the STEP 1 study of semaglutide (Wegovy), completion rates were high despite the GI side-effect profile, and average weight reductions were substantial over 68–72 weeks. How effective weight loss injections are is a reasonable next question once you've weighed the negative effects, because the two have to be read together.

That said, a minority of people do stop treatment because side effects feel unmanageable. The structured titration schedule (where doses start low and increase gradually) is specifically designed to reduce that likelihood. A prescriber's job includes monitoring how you're tolerating treatment and adjusting accordingly. This is one reason why buying from cut-price sources without clinical oversight carries real risk: there is nobody reviewing whether you're tolerating the medicine or whether your dose should be held.

For practical questions about what starting out looks like (including what arrives (a plain, unbranded box via DPD with tracking, containing the pre-filled KwikPen or Wegovy pen)) the weight loss injection guide covers the process from consultation to first use.

Which groups face the highest risk of negative effects?

Several factors raise the risk profile or create absolute contraindications. Pregnancy is one: these medicines are not recommended during pregnancy, and the guidance is to stop treatment and use effective contraception. Breastfeeding and active attempts to conceive are in the same category. Under-18s are outside the licensed population entirely.

A personal or close family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) is a contraindication that a prescriber will ask about directly. Pre-existing pancreatitis or certain inflammatory bowel conditions also require careful discussion before starting. People with gastroparesis (already slowed stomach emptying) face additional considerations because both tirzepatide and semaglutide slow gastric emptying further.

For anyone with a complex medical history, the clinical FAQs address common concerns, and a prescriber at our clinical team reviews every consultation personally. The NHS publishes patient-level information on both medicines, the NHS tirzepatide page is a reliable starting point for cross-checking anything raised here. If any of the risk factors above apply to you, that detail goes into your consultation so the prescriber can weigh it properly rather than missing it.